MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
June 05, 2020 07:30 ET
|
MacroGenics, Inc.
Rockville, MD, June 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia
June 03, 2020 16:05 ET
|
MacroGenics, Inc.
Rockville, MD, June 03, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer
May 28, 2020 07:30 ET
|
MacroGenics, Inc.
- Advisory committee meeting not required; PDUFA goal date unchanged Rockville, MD, May 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical...
MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia
May 27, 2020 07:30 ET
|
MacroGenics, Inc.
Rockville, MD, May 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO
May 21, 2020 16:05 ET
|
MacroGenics, Inc.
Rockville, MD, May 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting
May 13, 2020 17:10 ET
|
MacroGenics, Inc.
Rockville, MD, May 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results
May 05, 2020 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, Md., May 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting
April 29, 2020 16:01 ET
|
MacroGenics, Inc.
Rockville, MD, April 29, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format
April 28, 2020 16:01 ET
|
MacroGenics, Inc.
Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call
April 28, 2020 07:30 ET
|
MacroGenics, Inc.
Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...